Greenleaf Trust Has $463,000 Stake in Sanofi (NASDAQ:SNY)

Greenleaf Trust reduced its stake in shares of Sanofi (NASDAQ:SNY) by 30.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,592 shares of the company’s stock after selling 4,222 shares during the period. Greenleaf Trust’s holdings in Sanofi were worth $463,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in SNY. Stablepoint Partners LLC raised its stake in shares of Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after acquiring an additional 189 shares in the last quarter. Abel Hall LLC raised its position in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares during the period. PDS Planning Inc lifted its stake in shares of Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after buying an additional 200 shares during the last quarter. Eagle Ridge Investment Management boosted its holdings in shares of Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after buying an additional 203 shares during the period. Finally, Financial Advocates Investment Management grew its stake in Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after buying an additional 206 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Trading Up 0.3 %

Shares of SNY opened at $53.50 on Wednesday. The stock’s 50-day moving average price is $49.44 and its 200 day moving average price is $52.34. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market capitalization of $135.77 billion, a price-to-earnings ratio of 21.49, a P/E/G ratio of 1.26 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, research analysts predict that Sanofi will post 4.34 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on SNY shares. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.